Celgene drops patent suit against Dr Reddy’s over Revlimid generic

Intellectual Property 2022-02-25 11:15 am By Cat Fredenburgh | Melbourne

Bristol-Myers Squibb unit Celgene has dropped a lawsuit accusing Indian generics company Dr Reddy’s Laboraties of threatening to infringe its patent for Revlimid with the planned launch of a generic version of the blockbuster cancer drug in Australia.